CDMO competition among biotech companies intensifies; Korean companies all expand factories = South Korea

South Korean pharmaceutical and biotech companies are working to strengthen their production facilities in order to maintain their competitiveness. In response to an increase in orders for outsourced production, Samsung Biologics announced in June that it would open its 4th plant in Songdo (Songdo).
Following the start of full operation at the plant, the company is currently constructing its fifth factory, which is scheduled to be completed in April 2025. Once the fifth factory is completed, the company's total production capacity will increase to 784,000 liters.
. On the 18th, ST Farm is constructing a second oligonucleotide therapeutic drug manufacturing building on the premises of its Panwol office in Gyeonggi-do. The factory was completed and was planned twice.
Once the current expansion is completed, the company's production scale will increase to approximately 14 mol, making it the world's No. 1 producer of oligonucleotide therapeutic drugs.
SK Farm Teco recently announced that it is a US-based cell and gene therapy (CGT) CD company.
Acquired CBM, a US company specializing in MO. CBM is building a 65,000 square meter factory in Pennsylvania that will be the world's largest single CGT production facility.
A person involved in the pharmaceutical and biotechnology industries said, ``Developing new drugs requires advanced technological capabilities to handle molecules with complex shapes. Therefore, small and medium-sized pharmaceutical and biotech companies are concentrating on new drug development.
"There is a tendency to outsource production to CDMO companies."